Last reviewed 2026-04-23 · How we verify

DEP114

EMS · Phase 3 active Small molecule

DEP114 is an investigational immunotherapeutic agent designed to modulate immune responses, though its precise mechanism remains proprietary.

At a glance

Generic name	DEP114
Sponsor	EMS
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Limited public information is available on DEP114's exact molecular mechanism. As a Phase 3 compound from EMS, it is likely a targeted immunotherapy or checkpoint modulator, but without disclosed target or mechanism details, the specific pathway of action cannot be reliably characterized.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DEP114 CI brief — competitive landscape report
DEP114 updates RSS · CI watch RSS
EMS portfolio CI